VR Adviser’s Corvus Pharmaceuticals CRVS Stock Holding History

VR Adviser’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-250,000	Closed	-$603K	–	29
2021 Q4	$603K	Sell	250,000 -3,177,461	-93%	-$12.3M	0.08%	26
2021 Q3	$16.6M	Buy	+3,427,461	New	+$10.1M	2.13%	16

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

VR Adviser's CRVS Position: Q1 2022 in Review

VR Adviser sold out of Corvus Pharmaceuticals (CRVS) in Q1 2022, closing a stake of 250,000 shares — an estimated $603K sold.

VR Adviser first reported a position in CRVS in Q3 2021 and held it in 2 quarters. The position peaked at $16.6M in Q3 2021. 57 funds tracked by Wall St. Rank hold CRVS as of Q1 2022.

VR Adviser reported no remaining Corvus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
VR Adviser sold 250,000 Corvus Pharmaceuticals shares in Q1 2022, an estimated $603K.
VR Adviser first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 2 quarters.
VR Adviser's Corvus Pharmaceuticals position peaked at $16.6M in Q3 2021.
57 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2022.

Based on VR Adviser's 13F filing for Q1 2022, filed 16 May 2022.